InSightec tests ExAblate therapy in liver and bone cancer trials:
This article was originally published in Clinica
Israel-based InSightec has initiated two clinical trials in Europe evaluating the benefit of its ExAblate 2000 ablation therapy as a treatment for liver cancer and pain palliation in metastatic bone tumours. Up to 20 patients will be recruited onto each trial, which will be conducted at the Charite Hospital in Berlin, Germany, and St Mary's Hospital in London, UK. ExAblate 2000 uses MRI-guided high-focused ultrasound (MRgFUS) to thermally ablate tissue without the need for surgery. To date, the system, which is compatible with GE Healthcare's Signa MR system, is only approved to treat uterine fibroids.
You may also be interested in...
Cilta-cel maintained high response rates in longer-term multiple myeloma data, but ide-cel causes less cytokine release syndrome and severe neurotoxicity – and it has a March decision date at the US FDA.
Our updated graphic tracker of key developments from the leading vaccine candidates.
Pathway open for drug as post-covalent BTK option as Loxo gears up for "risky" Phase III head-to-head study in Q1 2021.